Okogen completes funding for phase 2b clinical program for acute infectious conjunctivitis

Okogen announced completion of $3.3 million in financing to advance the company through its phase 2b clinical program for acute infectious conjunctivitis, as well as support development of an AI-driven image evaluation platform.

“This milestone reinforces our commitment to delivering comprehensive therapeutic solutions for patients suffering from [acute infectious conjunctivitis],” Joshua Moriarty, Okogen’s CEO, said in a company press release. “Our focus remains on developing innovative, first-in-class products that improve outcomes for patients and efficiency for providers alike.”

According to the release, the series B funding will allow Okogen to transition from a single-asset company focused on the viral conjunctivitis treatment OKG-301 to a broader platform that includes a new AI-enabled image evaluation tool and the development of OKG-0303, a triple-combination eye drop. Clinical data from the phase 2b program is expected in late 2025.

“Our AI-enabled platform offers a comprehensive solution to aid in patient evaluation while delivering time and cost savings for patients, payers and health care providers,” Bradford Conlan, MS, Okogen’s co-founder and executive chairman, said in the release.

The company also announced the relocation of its headquarters from San Diego to Plano, Texas, moving it closer to critical resources and infrastructure.

Published by:

Read more about

This post was originally published on this site